Literature DB >> 29618643

Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.

Luis R Castillo-Menendez1, Kristen Witt1, Nicole Espy1, Amy Princiotto1, Navid Madani1, Beatriz Pacheco2, Andrés Finzi2, Joseph Sodroski3,4.   

Abstract

The mature envelope glycoprotein (Env) spike on the surfaces of human immunodeficiency virus type 1 (HIV-1)-infected cells and virions is derived from proteolytic cleavage of a trimeric gp160 glycoprotein precursor. In these studies, we compared the conformations of cleaved and uncleaved membrane Envs with truncated cytoplasmic tails to those of stabilized soluble gp140 SOSIP.664 Env trimers. Deletion of the gp41 cytoplasmic tail did not significantly affect the sensitivity of viruses with the HIV-1AD8 Env to inhibition by antibodies or a CD4-mimetic compound. After glutaraldehyde fixation and purification from membranes, a cleaved Env exhibited a hydrodynamic radius of ∼10 nm and an antibody-binding profile largely consistent with that expected based on virus neutralization sensitivity. The purified cleaved Env trimers exhibited a hollow architecture with a central void near the trimer axis. Uncleaved Env, cross-linked and purified in parallel, exhibited a hydrodynamic radius similar to that of the cleaved Env. However, the uncleaved Env was recognized by poorly neutralizing antibodies and appeared by negative-stain electron microscopy to sample multiple conformations. Compared with membrane Envs, stabilized soluble gp140 SOSIP.664 Env trimers appear to be more compact, as reflected in their smaller hydrodynamic radii and negative-stain electron microscopy structures. The antigenic features of the soluble gp140 SOSIP.664 Env trimers differed from those of the cleaved membrane Env, particularly in gp120 V3 and some CD4-binding-site epitopes. Thus, proteolytic maturation allows the membrane-anchored Env to achieve a conformation that retains functional metastability but masks epitopes for poorly neutralizing antibodies.IMPORTANCE The entry of human immunodeficiency virus type 1 (HIV-1) into host cells is mediated by the envelope glycoprotein (Env) spike on the surface of the virus. Host antibodies elicited during natural HIV-1 infection or by vaccination can potentially recognize the Env spike and block HIV-1 infection. However, the changing shape of the HIV-1 Env spike protects the virus from antibody binding. Understanding the shapes of natural and man-made preparations of HIV-1 Envs will assist the development of effective vaccines against the virus. Here, we evaluate the effects of several Env modifications commonly used to produce Env preparations for vaccine studies and the determination of structure. We found that the cleavage of the HIV-1 Env precursor helps Env to assume its natural shape, which resists the binding of many commonly elicited antibodies. Stabilized soluble Envs exhibit more compact shapes but expose some Env elements differently than the natural Env.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; antibody; conformation; cytoplasmic tail; envelope glycoprotein; proteolytic maturation

Mesh:

Substances:

Year:  2018        PMID: 29618643      PMCID: PMC5974486          DOI: 10.1128/JVI.00277-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  126 in total

1.  Identification of two sequences in the cytoplasmic tail of the human immunodeficiency virus type 1 envelope glycoprotein that inhibit cell surface expression.

Authors:  A Bültmann; W Muranyi; B Seed; J Haas
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.

Authors:  Shi-Hua Xiang; Najah Doka; Rabeéa K Choudhary; Joseph Sodroski; James E Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2002-11-01       Impact factor: 2.205

3.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

4.  Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Authors:  Florian Klein; Ron Diskin; Johannes F Scheid; Christian Gaebler; Hugo Mouquet; Ivelin S Georgiev; Marie Pancera; Tongqing Zhou; Reha-Baris Incesu; Brooks Zhongzheng Fu; Priyanthi N P Gnanapragasam; Thiago Y Oliveira; Michael S Seaman; Peter D Kwong; Pamela J Bjorkman; Michel C Nussenzweig
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

5.  Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes.

Authors:  L Miranda; J Wolf; S Pichuantes; R Duke; A Franzusoff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

6.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

8.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Authors:  Rajesh P Ringe; Rogier W Sanders; Anila Yasmeen; Helen J Kim; Jeong Hyun Lee; Albert Cupo; Jacob Korzun; Ronald Derking; Thijs van Montfort; Jean-Philippe Julien; Ian A Wilson; Per Johan Klasse; Andrew B Ward; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

9.  Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.

Authors:  Penny L Moore; Nthabeleng Ranchobe; Bronwen E Lambson; Elin S Gray; Eleanor Cave; Melissa-Rose Abrahams; Gama Bandawe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

10.  A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Authors:  Rogier W Sanders; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Anila Yasmeen; Natalia de Val; Helen J Kim; Claudia Blattner; Alba Torrents de la Peña; Jacob Korzun; Michael Golabek; Kevin de Los Reyes; Thomas J Ketas; Marit J van Gils; C Richter King; Ian A Wilson; Andrew B Ward; P J Klasse; John P Moore
Journal:  PLoS Pathog       Date:  2013-09-19       Impact factor: 6.823

View more
  24 in total

1.  Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.

Authors:  Maolin Lu; Xiaochu Ma; Nick Reichard; Daniel S Terry; James Arthos; Amos B Smith; Joseph G Sodroski; Scott C Blanchard; Walther Mothes
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

2.  Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins.

Authors:  Shitao Zou; Shijian Zhang; Althea Gaffney; Haitao Ding; Maolin Lu; Jonathan R Grover; Mark Farrell; Hanh T Nguyen; Connie Zhao; Saumya Anang; Meiqing Zhao; Mohammadjavad Mohammadi; Scott C Blanchard; Cameron Abrams; Navid Madani; Walther Mothes; John C Kappes; Amos B Smith; Joseph Sodroski
Journal:  J Virol       Date:  2020-05-04       Impact factor: 5.103

3.  Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function.

Authors:  Hanh T Nguyen; Nirmin Alsahafi; Andrés Finzi; Joseph G Sodroski
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

4.  Conformational Differences between Functional Human Immunodeficiency Virus Envelope Glycoprotein Trimers and Stabilized Soluble Trimers.

Authors:  Luis R Castillo-Menendez; Hanh T Nguyen; Joseph Sodroski
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

5.  Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.

Authors:  Connie Zhao; Amy M Princiotto; Hanh T Nguyen; Shitao Zou; Meiqing Lily Zhao; Shijian Zhang; Alon Herschhorn; Mark Farrell; Karanbir Pahil; Bruno Melillo; Somisetti V Sambasivarao; Cameron Abrams; Amos B Smith; Navid Madani; Joseph Sodroski
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

6.  Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.

Authors:  S Munir Alam; Kenneth Cronin; Robert Parks; Kara Anasti; Haitao Ding; Eden P Go; Heather Desaire; Amanda Eaton; David Montefiori; Joseph Sodroski; John Kappes; Barton F Haynes; Kevin O Saunders
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

7.  Interaction Interface of Mason-Pfizer Monkey Virus Matrix and Envelope Proteins.

Authors:  Jan Prchal; Jakub Sýs; Petra Junková; Jan Lipov; Tomáš Ruml
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

8.  Probing the Structure of the HIV-1 Envelope Trimer Using Aspartate Scanning Mutagenesis.

Authors:  Raksha Das; Rohini Datta; Raghavan Varadarajan
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

Review 9.  The Conformational States of the HIV-1 Envelope Glycoproteins.

Authors:  Qian Wang; Andrés Finzi; Joseph Sodroski
Journal:  Trends Microbiol       Date:  2020-05-14       Impact factor: 17.079

10.  Dual Pathways of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trafficking Modulate the Selective Exclusion of Uncleaved Oligomers from Virions.

Authors:  Shijian Zhang; Hanh T Nguyen; Haitao Ding; Jia Wang; Shitao Zou; Lihong Liu; Debjani Guha; Dana Gabuzda; David D Ho; John C Kappes; Joseph Sodroski
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.